Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Glioblastoma
IDH-wildtype disease that almost always recurs: EGFR, the blood-brain barrier and cell therapy attempts.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:24 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
465
Phase 1 to 3, interventional
For relapsed or refractory disease
38%
177 trial titles name relapsed, refractory or recurrent disease
Led by industry
28%
128 trials with a company as lead sponsor
34 of the 465 glioblastoma trials are Phase 3; 43 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of glioblastoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 134 of 465 trials name no segment and are listed as Untagged.
Segment:All1L1L · Adjuvant1L · Maintenance1L · Relapsed or refractory2L+2L+ · Advanced or metastaticAdjuvantAdvanced or metastaticEGFR · 1LEGFR · Advanced or metastaticEGFR · Relapsed or refractoryIDH-wildtypeIDH-wildtype · 1LIDH-wildtype · 1L · Relapsed or refractoryIDH-wildtype · Advanced or metastaticIDH-wildtype · Relapsed or refractoryLocally advancedMaintenanceMGMTMGMT · 1LMGMT · 1L · AdjuvantMGMT · 1L · Relapsed or refractoryMGMT · AdjuvantMGMT · Advanced or metastatic
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Temozolomide GT Medical Technologies, Inc. | Untagged | Small molecule | Ph3 | NCT07195591, NCT05106296, NCT03491683, NCT02177578 +24 |
| Temozolomide Sabine Mueller, MD, PhD | 1L | Small molecule | Ph3 | NCT07389278, NCT06556563, NCT02152982, NCT04216329 +21 |
| Bevacizumab BioNTech SE | Relapsed or refractory | Antibody | Ph3 | NCT07297212, NCT02974621, NCT06329570, NCT02142803 +11 |
| Temozolomide CarThera | Relapsed or refractory | Small molecule | Ph3 | NCT05902169, NCT07297212, NCT05629702, NCT07859059 +10 |
| Lomustine CarThera | Relapsed or refractory | Other or not recognised | Ph3 | NCT05902169, NCT06325683, NCT07145112, NCT05326464 +4 |
| Temozolomide Istituto Oncologico Veneto IRCCS | IDH-wildtype | Small molecule | Ph3 | NCT06095375, NCT07708961, NCT07758062, NCT04623931 +3 |
| Temozolomide Theodore S. Johnson | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT04049669, NCT03970447, NCT05765812, NCT03011671 +3 |
| Temozolomide National Cancer Institute (NCI) | MGMT · 1L | Small molecule | Ph2/Ph3 | NCT04396860, NCT07326566, NCT06991101, NCT05685004 +1 |
| Pembrolizumab NovoCure GmbH | 1L | Antibody | Ph3 | NCT06556563, NCT02287428, NCT03426891, NCT03018288 |
| Temozolomide National Cancer Institute (NCI) | IDH-wildtype · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT05432804, NCT07349693, NCT06410248, NCT05236036 |
| Lomustine European Organisation for Research and Treatment of Cancer - EORTC | Untagged | Other or not recognised | Ph3 | NCT05904119, NCT06336291, NCT06336291 |
| Lomustine Theodore S. Johnson | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT04049669, NCT03970447 |
| Temozolomide Beijing Tiantan Hospital | IDH-wildtype · 1L | Small molecule | Ph2/Ph3 | NCT07873996, NCT07452458 |
| Temozolomide Ivy Brain Tumor Center | MGMT | Small molecule | Ph3 | NCT06388733, NCT06504381 |
| Temozolomide Nationwide Children's Hospital | Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT05843253, NCT07605364 |
| Veliparib National Cancer Institute (NCI) | 1L | Small molecule | Ph2/Ph3 | NCT02152982, NCT03581292 |
| 5-aminolévulinique acid Hospices Civils de Lyon | Untagged | Other or not recognised | Ph3 | NCT01811121 |
| Activated T lymphocyte GC Cell Corporation | 1L | Other or not recognised | Ph3 | NCT00807027 |
| ADI-PEG 20 Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| AZD1390 Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| Cerebraca wafer Everfront Biotech Co., Ltd. | IDH-wildtype · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT07349693 |
| Cisplatin combined with Etoposide Beijing Pearl Biotechnology Limited Liability Company | Untagged | Other or not recognised | Ph2/Ph3 | NCT06105619 |
| Extended Release Flucytosine NRG Oncology | 1L | Other or not recognised | Ph2/Ph3 | NCT04105374 |
| Ferumoxytol Jonsson Comprehensive Cancer Center | Advanced or metastatic | Other or not recognised | Ph3 | NCT07461948 |
| Ipilimumab National Cancer Institute (NCI) | MGMT · 1L | Antibody | Ph2/Ph3 | NCT04396860 |
| LAM561 Laminar Pharmaceuticals | Untagged | Other or not recognised | Ph2/Ph3 | NCT04250922 |
| Lomustine NRG Oncology | MGMT · 1L | Other or not recognised | Ph3 | NCT05095376 |
| Lomustine Vastra Gotaland Region | IDH-wildtype | Other or not recognised | Ph3 | NCT06419946 |
| Microbubble NaviFUS Corporation | Relapsed or refractory | Other or not recognised | Ph3 | NCT06496971 |
| Mycophenolate Mofetil Alliance for Clinical Trials in Oncology | Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT07605364 |
| Niraparib Ivy Brain Tumor Center | MGMT | Small molecule | Ph3 | NCT06388733 |
| Nivolumab National Cancer Institute (NCI) | MGMT · 1L | Antibody | Ph2/Ph3 | NCT04396860 |
| Paxalisib Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT03970447 |
| Physician's Choice of Salvage Therapy - carboplatin DelMar Pharmaceuticals, Inc. | Relapsed or refractory | Other or not recognised | Ph3 | NCT03149575 |
| Physician's Choice of Salvage Therapy - lomustine DelMar Pharmaceuticals, Inc. | Relapsed or refractory | Other or not recognised | Ph3 | NCT03149575 |
| Physician's Choice of Salvage Therapy - temozolomide DelMar Pharmaceuticals, Inc. | Relapsed or refractory | Small molecule | Ph3 | NCT03149575 |
| PLB1001 Beijing Pearl Biotechnology Limited Liability Company | Untagged | Other or not recognised | Ph2/Ph3 | NCT06105619 |
| Regorafenib Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT03970447 |
| safusidenib Nuvation Bio Inc. | Maintenance | Small molecule | Ph3 | NCT05303519 |
| Tinostamustine Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| TLX-101-Tx + Lomustine Telix Pharmaceuticals (Innovations) Pty Limited | Relapsed or refractory | Other or not recognised | Ph3 | NCT07100730 |
| TMZ Laminar Pharmaceuticals | Untagged | Other or not recognised | Ph2/Ph3 | NCT04250922 |
| Tofacitinib University of Texas Southwestern Medical Center | Relapsed or refractory | Small molecule | Ph3 | NCT05326464 |
| Tris-CAR-T cell injection Beijing Tiantan Hospital | IDH-wildtype · 1L | Cell therapy | Ph2/Ph3 | NCT07873996 |
| Troriluzole Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| TVI-Brain-1 TVAX Biomedical | MGMT · 1L | Other or not recognised | Ph2/Ph3 | NCT05685004 |
| VAL-083 Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| VAL-083, Dianhydrogalactitol DelMar Pharmaceuticals, Inc. | Relapsed or refractory | Other or not recognised | Ph3 | NCT03149575 |
| Vocimagene Amiretrorepvec NRG Oncology | 1L | Other or not recognised | Ph2/Ph3 | NCT04105374 |
| VT1021 Global Coalition for Adaptive Research | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03970447 |
| Nivolumab National Cancer Institute (NCI) | Relapsed or refractory | Antibody | Ph2 | NCT06325683, NCT06896110, NCT04606316, NCT07031765 +4 |
| Atezolizumab Darell Bigner | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT04160494, NCT05039281, NCT06069726, NCT07263438 +1 |
| Pembrolizumab University of Florida | Relapsed or refractory | Antibody | Ph2 | NCT06558214, NCT04977375, NCT02337686, NCT04201873 +1 |
| Pembrolizumab Mayo Clinic | Untagged | Antibody | Ph2 | NCT03197506, NCT07762716, NCT05084430, NCT03347617 +1 |
| Bevacizumab Unity Health Toronto | Untagged | Antibody | Ph1/Ph2 | NCT07909811, NCT07831187, NCT01837862, NCT01743950 |
| abemaciclib Tango Therapeutics, Inc. | Untagged | Small molecule | Ph1/Ph2 | NCT06810544, NCT02977780, NCT04118036 |
| Azeliragon Cantex Pharmaceuticals | 1L | Other or not recognised | Ph1/Ph2 | NCT05635734, NCT05635734, NCT05635734 |
| Ipilimumab Gilbert Youssef | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT04606316, NCT04003649, NCT03233152 |
| Irinotecan Inova Health Care Services | Relapsed or refractory | Other or not recognised | Ph2 | NCT07831369, NCT02192359, NCT04238819 |
| L19TNF Philogen S.p.A. | Untagged | Other or not recognised | Ph2 | NCT06336291, NCT06336291, NCT06336291 |
Showing the 60 most advanced of 566 programs.
Assets over time
465 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Temozolomide | GT Medical Technologies, Inc. | |
| Bevacizumab | Unity Health Toronto | |
| Lomustine | CarThera | |
| Ipilimumab | National Cancer Institute (NCI) | |
| Niraparib | Ivy Brain Tumor Center | |
| Ferumoxytol | Jonsson Comprehensive Cancer Center | |
| VAL-083, Dianhydrogalactitol | DelMar Pharmaceuticals, Inc. | |
| safusidenib | Nuvation Bio Inc. | |
| Tris-CAR-T cell injection | Beijing Tiantan Hospital | |
| TVI-Brain-1 | TVAX Biomedical | |
| Cerebraca wafer | Everfront Biotech Co., Ltd. | |
| TLX-101-Tx + Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | |
| Tofacitinib | University of Texas Southwestern Medical Center | |
| Extended Release Flucytosine | NRG Oncology | |
| PLB1001 | Beijing Pearl Biotechnology Limited Liability Company | |
| LAM561 | Laminar Pharmaceuticals | |
| Activated T lymphocyte | GC Cell Corporation | |
| 5-aminolévulinique acid | Hospices Civils de Lyon | |
| Pembrolizumab | University of Florida | |
| Nivolumab | Andrew P. Groves | |
| D2C7-IT | Darell Bigner | |
| Atezolizumab | M.D. Anderson Cancer Center | |
| Metformin | Weill Medical College of Cornell University | |
| Ad-RTS-hIL-12 | Alaunos Therapeutics | |
| ADI-PEG 20 | Sabine Mueller, MD, PhD | |
| Selinexor | National Cancer Institute (NCI) | |
| M032 | University of Alabama at Birmingham | |
| Indoximod | Theodore S. Johnson | |
| EGFR/EGFRvIII Inhibitor WSD0922-FU | Mayo Clinic | |
| Cemiplimab | Washington University School of Medicine |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| CAR-T · NCT07873996 Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Beijing Tiantan Hospital | not yet recruiting | 2026-10-14 | 2030-10-15 |
| NCT07605364 Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer No sites listed Decision brief → | Ph2/Ph3 | Alliance for Clinical Trials in Oncology | not yet recruiting | 2026-05-26 | 2029-09-30 |
| NCT07461948 Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients Single-country: United States (1 site) Decision brief → | Ph3 | Jonsson Comprehensive Cancer Center | recruiting | 2026-03-10 | 2028-10-27 |
| NCT07452458 Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Single-country: United States (54 sites) Decision brief → | Ph3 | NRG Oncology | recruiting | 2026-03-05 | 2030-01-15 |
| BrainUS-AI · NCT07376304 Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI No sites listed Decision brief → | Ph3 | Hospital del Rio Hortega | not yet recruiting | 2026-01-29 | 2027-12 |
| Cerebraca-02/3 · NCT07349693 Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | Everfront Biotech Co., Ltd. | not yet recruiting | 2026-01-20 | 2029-03-30 |
| BRIDGES · NCT07195591 Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care Single-country: United States (22 sites) Decision brief → | Ph3 | GT Medical Technologies, Inc. | recruiting | 2025-09-26 | 2031-12 |
| IPAX BrIGHT · NCT07100730 Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma 4 countries, 0% of sites in the US Decision brief → | Ph3 | Telix Pharmaceuticals (Innovations) Pty Limited | recruiting | 2025-08-03 | 2027-07 |
| EF-41 · NCT06556563 EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma 12 countries, 35% of sites in the US Decision brief → | Ph3 | NovoCure GmbH | active not recruiting | 2024-08-16 | 2029-04 |
| NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Single-country: Taiwan (2 sites) Decision brief → | Ph3 | NaviFUS Corporation | recruiting | 2024-07-11 | 2026-12-31 |
| NCT06448286 PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Single-country: United States (1 site) Decision brief → | Ph3 | Jonsson Comprehensive Cancer Center | not yet recruiting | 2024-06-07 | 2030-12-01 |
| NCT06419946 Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma 4 countries, 0% of sites in the US Decision brief → | Ph3 | Vastra Gotaland Region | recruiting | 2024-05-17 | 2031-12-15 |
| NCT06388733 A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma 11 countries, 34% of sites in the US Decision brief → | Ph3 | Ivy Brain Tumor Center | active not recruiting | 2024-04-29 | 2027-12 |
| NCT06105619 A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Beijing Pearl Biotechnology Limited Liability Company | active not recruiting | 2023-10-27 | 2023-04-01 |
| LEGATO · NCT05904119 Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study 11 countries, 0% of sites in the US Decision brief → | Ph3 | European Organisation for Research and Treatment of Cancer - EORTC | recruiting | 2023-06-15 | 2027-09 |
| SONOBIRD · NCT05902169 Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM 11 countries, 41% of sites in the US Decision brief → | Ph3 | CarThera | active not recruiting | 2023-06-13 | 2028-01-28 |
| NCT05685004 Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Single-country: United States (8 sites) Decision brief → | Ph2/Ph3 | TVAX Biomedical | active not recruiting | 2023-01-13 | 2030-11 |
| AFGB2 · NCT05669820 Antisecretory Factor Glioblastoma Phase 2 Single-country: Sweden (1 site) Decision brief → | Ph2/Ph3 | Peter Siesjö | recruiting | 2023-01-03 | 2026-12-01 |
| NCT05326464 Tofacitinib in Recurrent GBM Patients Single-country: United States (1 site) Decision brief → | Ph3 | University of Texas Southwestern Medical Center | completed | 2022-04-13 | 2025-02-18 |
| SIGMA · NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) 3 countries, 75% of sites in the US Decision brief → | Ph3 | Nuvation Bio Inc. | recruiting | 2022-03-31 | 2028-12-01 |
| NCT05271240 Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Single-country: United States (1 site) Decision brief → | Ph3 | Northwell Health | recruiting | 2022-03-08 | 2027-04-01 |
| NCT05095376 Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma 2 countries, 100% of sites in the US Decision brief → | Ph3 | NRG Oncology | active not recruiting | 2021-10-27 | 2026-02-12 |
| NCT04396860 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Single-country: United States (285 sites) Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | completed | 2020-05-21 | 2023-01-13 |
| CLINGLIO · NCT04250922 LAM561 With RT and TMZ for Adults With Glioblastoma 5 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Laminar Pharmaceuticals | active not recruiting | 2020-01-31 | 2026-01-15 |
| NCT04105374 Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2/Ph3 | NRG Oncology | withdrawn | 2019-09-26 | 2025-11-30 |
| GBM AGILE · NCT03970447 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma 6 countries, 67% of sites in the US Decision brief → | Ph2/Ph3 | Global Coalition for Adaptive Research | recruiting | 2019-05-31 | 2028-06 |
| StrateGlio · NCT03663725 Treatment Intensification With Temozolomide in Adults With a Glioblastoma Single-country: France (17 sites) Decision brief → | Ph3 | Centre Oscar Lambret | active not recruiting | 2018-09-10 | 2027-06 |
| STAR-3 · NCT03149575 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Single-country: United States (5 sites) Decision brief → | Ph3 | DelMar Pharmaceuticals, Inc. | terminated | 2017-05-11 | 2019-05-31 |
| RE-GEND · NCT02761070 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Single-country: Japan (37 sites) Decision brief → | Ph3 | Kyorin University | completed | 2016-05-04 | 2025-04-17 |
| INTRAGO-II · NCT02685605 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme 8 countries, 26% of sites in the US Decision brief → | Ph3 | Universitätsmedizin Mannheim | active not recruiting | 2016-02-19 | 2025-11 |
| NCT02152982 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme 2 countries, 100% of sites in the US Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-06-02 | 2021-12-01 |
| RESECT · NCT01811121 MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS Single-country: France (1 site) Decision brief → | Ph3 | Hospices Civils de Lyon | completed | 2013-03-14 | 2013-03 |
| SPECTRO GLIO · NCT01507506 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Single-country: France (12 sites) Decision brief → | Ph3 | Institut Claudius Regaud | terminated | 2012-01-11 | 2020-01-02 |
| NCT00807027 Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Single-country: South Korea (7 sites) Decision brief → | Ph3 | GC Cell Corporation | completed | 2008-12-11 | 2012-10 |
| ALERT-1 · NCT07902037 A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) No sites listed Decision brief → | Ph1/Ph2 | Siren Biotechnology | not yet recruiting | 2026-10-28 | 2030-01 |
| STAR-VACC · NCT07888647 IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas Single-country: Germany (13 sites) Decision brief → | Ph2 | German Cancer Research Center | not yet recruiting | 2026-10-22 | 2034-02-01 |
| NCT07859059 Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Nebraska | not yet recruiting | 2026-10-05 | 2030-06-01 |
| NCT07831187 Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence Single-country: China (1 site) Decision brief → | Ph1/Ph2 | First Affiliated Hospital of Wenzhou Medical University | not yet recruiting | 2026-09-21 | 2029-09-30 |
| NCT07831369 VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma Single-country: United States (1 site) Decision brief → | Ph2 | Inova Health Care Services | recruiting | 2026-09-21 | 2027-09-30 |
| ENDURANCE · NCT07821112 Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® Single-country: United States (1 site) Decision brief → | Ph2 | University of California, Irvine | not yet recruiting | 2026-09-15 | 2027-10 |
| NCT07811297 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Advenchen Pharmaceuticals, LLC. | not yet recruiting | 2026-09-10 | 2030-09-01 |
| NCT07789379 Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma No sites listed Decision brief → | Ph2 | Wei Jiang | not yet recruiting | 2026-08-27 | 2028-10-01 |
| NCT07762716 Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | BreakBio Corp | not yet recruiting | 2026-08-13 | 2030-09 |
| ELITE · NCT07758062 Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma Single-country: China (1 site) Decision brief → | Ph2 | Tianjin Medical University General Hospital | not yet recruiting | 2026-08-11 | 2029-08-01 |
| NCT07754734 STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation No sites listed Decision brief → | Ph2 | Dongguan People's Hospital | not yet recruiting | 2026-08-10 | 2029-07-31 |
| NCT07751744 Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma No sites listed Decision brief → | Ph1/Ph2 | Jubilant Therapeutics Inc. | not yet recruiting | 2026-08-07 | 2030-03-31 |
| NCT07735819 Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma Single-country: United States (1 site) Decision brief → | Ph2 | Barbara Ann Karmanos Cancer Institute | not yet recruiting | 2026-07-30 | 2031-06-30 |
| NCT07715097 Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2 | Beijing Tricision Biotherapeutics Inc | not yet recruiting | 2026-07-20 | 2028-09-30 |
| NCT07708961 Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma Single-country: United States (3 sites) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2026-07-16 | 2036-08-31 |
| Nimotuzumab · NCT07707973 Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma No sites listed Decision brief → | Ph2 | Tianjin First Central Hospital | not yet recruiting | 2026-07-16 | 2028-01-03 |
| NCT07670026 Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression Single-country: China (1 site) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2026-06-25 | 2027-12-01 |
| NCT07628062 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation No sites listed Decision brief → | Ph2 | ImmunityBio, Inc. | not yet recruiting | 2026-06-04 | 2030-12-31 |
| NCT07620548 Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas Single-country: United States (2 sites) Decision brief → | Ph2 | Washington University School of Medicine | not yet recruiting | 2026-06-02 | 2031-05-31 |
| NOVA-GBM · NCT07604285 A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Myosin Therapeutics Inc. | not yet recruiting | 2026-05-22 | 2027-03 |
| NCT07569042 A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Single-country: Taiwan (3 sites) Decision brief → | Ph1/Ph2 | Novelwise Pharmaceutical Corporation | recruiting | 2026-05-06 | 2029-09-30 |
| NF118 · NCT07521657 Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma Single-country: United States (1 site) Decision brief → | Ph2 | University of Alabama at Birmingham | not yet recruiting | 2026-04-13 | 2031-01-01 |
| SELECT-2CAR · NCT07523529 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Biotech | recruiting | 2026-04-13 | 2027-04-14 |
| PRISM · NCT07511725 Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma Single-country: China (1 site) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2026-04-06 | 2028-01-04 |
| NCT07501559 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Jecho Biopharmaceuticals Co., Ltd. | recruiting | 2026-03-30 | 2030-04 |
| TEMPO · NCT07476794 Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma Single-country: Canada (1 site) Decision brief → | Ph2 | Sunnybrook Health Sciences Centre | recruiting | 2026-03-17 | 2027-10 |
| NCT07468136 Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Mayo Clinic | recruiting | 2026-03-12 | 2030-10-25 |
| NCT07462507 Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 Single-country: United States (1 site) Decision brief → | Ph2 | Washington University School of Medicine | recruiting | 2026-03-10 | 2031-06-30 |
| PRC · NCT07439172 Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. Single-country: United States (1 site) Decision brief → | Ph2 | Cooper Norcross Health | recruiting | 2026-02-27 | 2028-09 |
| NCT07431216 A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression No sites listed Decision brief → | Ph1/Ph2 | Starlight Therapeutics Inc. | not yet recruiting | 2026-02-24 | 2027-05-01 |
| NCT07416188 Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Institute of Neurological Disorders and Stroke (NINDS) | recruiting | 2026-02-18 | 2030-12-31 |
| SELECT-CAR-NK · NCT07410494 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2026-02-13 | 2027-12-28 |
| EBNK-ST-001 · NCT07410676 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2026-02-13 | 2028-12-21 |
| NCT07392957 Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Washington University School of Medicine | recruiting | 2026-02-06 | 2029-06-30 |
| NCT07389278 Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Sabine Mueller, MD, PhD | not yet recruiting | 2026-02-05 | 2032-06-30 |
| 5G-PEARL · NCT07391215 5G-PEARL: Paxalisib in Malignant Brain Tumours Single-country: United Kingdom (1 site) Decision brief → | Ph1/Ph2 | Institute of Cancer Research, United Kingdom | recruiting | 2026-02-05 | 2029-01-19 |
| GLIOMAX-101 · NCT07386002 The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma 2 countries, 25% of sites in the US Decision brief → | Ph2 | T-MAXIMUM Pharmaceutical Inc | not yet recruiting | 2026-02-04 | 2028-12-13 |
| NCT07365280 Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2 | ZSky Biotech Inc | not yet recruiting | 2026-01-26 | 2028-12-24 |
| AFGBMBiop · NCT07364786 Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma Single-country: Sweden (1 site) Decision brief → | Ph2 | Peter Siesjö | recruiting | 2026-01-23 | 2026-10 |
| OPTICAL · NCT07356973 Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma Single-country: United Kingdom (1 site) Decision brief → | Ph2 | CRISM Therapeutics LTD | recruiting | 2026-01-21 | 2029-05 |
| ADePT · NCT07346144 Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma 2 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Trogenix ltd | recruiting | 2026-01-16 | 2030-03 |
| MATVAC-1 · NCT07347210 Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma Single-country: France (4 sites) Decision brief → | Ph2 | Centre Hospitalier Universitaire de Besancon | not yet recruiting | 2026-01-16 | 2029-01 |
| NCT07326566 Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Single-country: United States (38 sites) Decision brief → | Ph2 | Black Diamond Therapeutics, Inc. | recruiting | 2026-01-08 | 2028-11 |
| NCT07318818 A Clinical Trial of P134 Cells in Recurrent Glioblastoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Tasly Pharmaceutical Group Co., Ltd | recruiting | 2026-01-06 | 2028-02-29 |
| NCT07301268 GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Single-country: United States (1 site) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-12-24 | 2029-09-01 |
| NCT07297212 A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma Single-country: China (6 sites) Decision brief → | Ph2 | BioNTech SE | recruiting | 2025-12-22 | 2028-01 |
| NCT07285044 The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Single-country: United States (1 site) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-12-16 | 2027-05-15 |
| ReVoGlio · NCT07284628 Vortioxetine for Newly Diagnosed Glioblastoma Single-country: Switzerland (1 site) Decision brief → | Ph2 | University of Zurich | recruiting | 2025-12-16 | 2029-06 |
| Phenix · NCT07263438 Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial Single-country: Switzerland (7 sites) Decision brief → | Ph2 | Centre Hospitalier Universitaire Vaudois | recruiting | 2025-12-04 | 2028-03-30 |
| NCT07225621 Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma Single-country: United States (11 sites) Decision brief → | Ph2 | Alpheus Medical, Inc. | recruiting | 2025-11-06 | 2027-12 |
| NCT07193654 Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread Single-country: China (1 site) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2025-09-26 | 2027-04-01 |
| STAR-GBM · NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Myosin Therapeutics Inc. | recruiting | 2025-09-22 | 2026-10-31 |
| NCT07180927 DLL3 CAR-T Therapy Targeting Brain Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2025-09-18 | 2028-05-31 |
| NCT07145047 Clinical Study of Oncolytic Virus in Glioblastoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Mianyang Central Hospital | recruiting | 2025-08-28 | 2025-12-31 |
| NCT07138001 Phase 2 Clinical Trial of KH617 No sites listed Decision brief → | Ph2 | Sichuan Honghe Biotechnology Co., Ltd. | not yet recruiting | 2025-08-22 | 2027-09 |
| NCT07130149 Sonodynamic-Chemoradiotherapy Integration in Glioblastoma Single-country: China (1 site) Decision brief → | Ph2 | Yingjuan Zheng | enrolling by invitation | 2025-08-19 | 2028-08-01 |
| PriCoTTF · NCT07120620 PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma Single-country: Germany (1 site) Decision brief → | Ph1/Ph2 | Sied Kebir | completed | 2025-08-13 | 2023-08-28 |
| NCT07093814 A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma Single-country: China (11 sites) Decision brief → | Ph1/Ph2 | Guangzhou Virotech Pharmaceutical Co., Ltd. | recruiting | 2025-07-30 | 2028-12-31 |
| NCT07003542 A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Single-country: United States (1 site) Decision brief → | Ph2 | Case Comprehensive Cancer Center | recruiting | 2025-06-04 | 2027-06 |
| NCT06991101 Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Single-country: United States (2 sites) Decision brief → | Ph2 | Baptist Health South Florida | recruiting | 2025-05-25 | 2030-12 |
| ADVICE · NCT06926075 Early Phase Study of KESONOTIDE™in Participants With Solid Tumours Single-country: Australia (3 sites) Decision brief → | Ph1/Ph2 | Filamon LTD | recruiting | 2025-04-13 | 2027-10-26 |
| NCT06914128 A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors 13 countries, 27% of sites in the US Decision brief → | Ph1/Ph2 | Bayer | recruiting | 2025-04-06 | 2029-06-18 |
| NCT06894225 Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature Single-country: Singapore (1 site) Decision brief → | Ph2 | National Neuroscience Institute | recruiting | 2025-03-25 | 2027-05 |
| NCT06855628 Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) Single-country: United States (1 site) Decision brief → | Ph2 | Stanford University | completed | 2025-03-04 | 2026-07-13 |
| ELITE-GBM · NCT06835803 Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial Single-country: United States (3 sites) Decision brief → | Ph2 | Brigham and Women's Hospital | recruiting | 2025-02-19 | 2028-03-31 |
| GIANT · NCT06816927 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab 2 countries, 75% of sites in the US Decision brief → | Ph2 | Duke University | recruiting | 2025-02-10 | 2029-06-01 |
| RABBIT · NCT06814496 Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | University of Arizona | recruiting | 2025-02-07 | 2030-05 |
| NCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss Single-country: United States (15 sites) Decision brief → | Ph1/Ph2 | Tango Therapeutics, Inc. | recruiting | 2025-02-05 | 2027-03-31 |
| EViDENCE-BT · NCT06804655 Pharmacoscopy for Patients With Refractory Primary Brain Tumors Single-country: Switzerland (3 sites) Decision brief → | Ph2 | University of Zurich | recruiting | 2025-02-03 | 2028-09-15 |
| NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) Single-country: United States (18 sites) Decision brief → | Ph2 | Diakonos Oncology Corporation | recruiting | 2025-02-03 | 2030-03 |
| NCT06672575 A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | recruiting | 2024-11-04 | 2028-01-31 |
| NCT06649851 G-CSF After Chemo-radiation in Patients With Glioblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Massachusetts General Hospital | recruiting | 2024-10-21 | 2027-01-31 |
| 5G-RUBY · NCT06630260 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Single-country: United Kingdom (3 sites) Decision brief → | Ph1/Ph2 | Institute of Cancer Research, United Kingdom | recruiting | 2024-10-08 | 2029-09-30 |
| NAVIG-1 · NCT06622434 New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study Single-country: France (3 sites) Decision brief → | Ph1/Ph2 | Assistance Publique - Hôpitaux de Paris | recruiting | 2024-10-02 | 2028-03-08 |
| LUPARPED · NCT06607692 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Single-country: Spain (1 site) Decision brief → | Ph1/Ph2 | Fundación de investigación HM | recruiting | 2024-09-23 | 2029-07 |
| OPTIMUS PRIME · NCT06558214 OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial Single-country: United States (1 site) Decision brief → | Ph2 | University of Florida | recruiting | 2024-08-16 | 2029-10 |
| NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer 6 countries, 30% of sites in the US Decision brief → | Ph1/Ph2 | GlaxoSmithKline | active not recruiting | 2024-07-26 | 2026-10-13 |
| NCT06504381 DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma Single-country: United States (5 sites) Decision brief → | Ph1/Ph2 | University of California, San Francisco | recruiting | 2024-07-16 | 2028-01-31 |
| GLADIATOR · NCT06492486 Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow Single-country: India (1 site) Decision brief → | Ph2 | Tata Memorial Centre | recruiting | 2024-07-09 | 2028-07-30 |
| CBT-I in PBT · NCT06439420 CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Single-country: United States (1 site) Decision brief → | Ph2 | Virginia Commonwealth University | completed | 2024-06-03 | 2025-09-25 |
| NCT06359379 Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Single-country: United States (6 sites) Decision brief → | Ph2 | Shuttle Pharmaceuticals, Inc. | terminated | 2024-04-11 | 2025-12-01 |
| NCT06356883 Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma Single-country: Canada (1 site) Decision brief → | Ph2 | Université de Sherbrooke | recruiting | 2024-04-10 | 2027-04 |
| GLIOSTELLA · NCT06336291 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence Single-country: United States (9 sites) Decision brief → | Ph2 | Philogen S.p.A. | active not recruiting | 2024-03-28 | 2026-06 |
| NCT06329570 Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | NaviFUS Corporation | suspended | 2024-03-26 | 2027-12-31 |
| NCT06325683 Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Single-country: United States (325 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | suspended | 2024-03-22 | 2029-07-15 |
| GABLE · NCT06319027 Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial Single-country: United States (18 sites) Decision brief → | Ph2 | ECOG-ACRIN Cancer Research Group | recruiting | 2024-03-19 | 2027-05-31 |
| NCT06264388 DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma Single-country: United States (1 site) Decision brief → | Ph2 | Ashish Shah | recruiting | 2024-02-20 | 2034-05-01 |
| NCT06177964 Lerapolturev (PVSRIPO) in GBM Single-country: United States (1 site) Decision brief → | Ph2 | Darell Bigner | recruiting | 2023-12-20 | 2029-02 |
| NCT06161519 PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | recruiting | 2023-12-08 | 2028-11-14 |
| NCT06161974 Study of Olutasidenib and Temozolomide in HGG 7 countries, 55% of sites in the US Decision brief → | Ph2 | Rigel Pharmaceuticals | recruiting | 2023-12-08 | 2029-06 |
| TCaP · NCT06157541 T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Single-country: Australia (4 sites) Decision brief → | Ph1/Ph2 | Queensland Institute of Medical Research | active not recruiting | 2023-12-06 | 2025-10-02 |
| NCT06147505 XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Dushu Lake Hospital Affiliated to Soochow University | active not recruiting | 2023-11-27 | 2026-08-31 |
| NCT06102525 A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma Single-country: South Korea (6 sites) Decision brief → | Ph1/Ph2 | Rznomics, Inc. | recruiting | 2023-10-26 | 2029-03 |
| MOAB · NCT06069726 A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial Single-country: United States (4 sites) Decision brief → | Ph2 | Duke University | recruiting | 2023-10-06 | 2028-01-01 |
| NCT06059690 Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Jonsson Comprehensive Cancer Center | recruiting | 2023-09-29 | 2027-09-30 |
| NCT06061809 N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Single-country: United States (4 sites) Decision brief → | Ph2 | ImmunityBio, Inc. | active not recruiting | 2023-09-29 | 2029-12-31 |
| NCT06058988 Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2023-09-28 | 2027-09-22 |
| NCT06047379 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Single-country: United States (8 sites) Decision brief → | Ph1/Ph2 | Neonc Technologies, Inc. | recruiting | 2023-09-21 | 2027-02-28 |
| NCT06011109 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Aveta Biomics, Inc. | active not recruiting | 2023-08-25 | 2026-12-31 |
| NCT06012695 NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma Single-country: Taiwan (4 sites) Decision brief → | Ph1/Ph2 | Novelwise Pharmaceutical Corporation | recruiting | 2023-08-25 | 2028-05-30 |
| NCT05986851 Azeliragon in MGMT Unmethylated Glioblastoma Single-country: United States (8 sites) Decision brief → | Ph2 | Cantex Pharmaceuticals | active not recruiting | 2023-08-14 | 2026-09-30 |
| NCT05969860 At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Single-country: United States (2 sites) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2023-08-01 | 2027-12-01 |
| NCT05956821 Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Miami | recruiting | 2023-07-21 | 2029-10-01 |
| NCT05941507 A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors 2 countries, 88% of sites in the US Decision brief → | Ph1/Ph2 | LigaChem Biosciences, Inc. | recruiting | 2023-07-12 | 2027-01 |
| NCT05929495 Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Single-country: Italy (1 site) Decision brief → | Ph2 | University of Milano Bicocca | recruiting | 2023-07-03 | 2026-01-01 |
| 14 · NCT05909618 Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases Single-country: Israel (1 site) Decision brief → | Ph2 | Sheba Medical Center | recruiting | 2023-06-18 | 2028-07-30 |
| NCT05879250 WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Single-country: United States (2 sites) Decision brief → | Ph2 | Northwestern University | recruiting | 2023-05-30 | 2027-12-27 |
| PRIDE · NCT05871021 Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma Single-country: Germany (9 sites) Decision brief → | Ph2 | University Hospital Tuebingen | active not recruiting | 2023-05-23 | 2028-12-31 |
| NCT05864534 Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma Single-country: United States (1 site) Decision brief → | Ph2 | Northwestern University | active not recruiting | 2023-05-18 | 2031-07-31 |
| NCT05843253 Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant 6 countries, 55% of sites in the US Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2023-05-06 | 2029-08-31 |
| NCT05781321 Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study Single-country: United States (8 sites) Decision brief → | Ph2 | Mayo Clinic | active not recruiting | 2023-03-23 | 2026-11-30 |
| NCT05765812 A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma 3 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Debiopharm International SA | recruiting | 2023-03-13 | 2028-09 |
| NCT05753007 A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients Single-country: United States (1 site) Decision brief → | Ph2 | Mclean Hospital | terminated | 2023-03-03 | 2025-02-11 |
| NCT05734560 D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Darell Bigner | recruiting | 2023-02-21 | 2026-10-31 |
| NCT05736406 A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma 2 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Hemerion Therapeutics | active not recruiting | 2023-02-21 | 2026-03-06 |
| NCT05708352 A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment Single-country: United States (5 sites) Decision brief → | Ph2 | Cedars-Sinai Medical Center | recruiting | 2023-02-01 | 2028-09-30 |